GlassScriptPhysician profile
Michael J Deluca
NPI 1053311936
$20,241.36
in general payments reported to CMS, 2019-2025
29 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,177 · 2021: $2,187 · 2022: $1,028 · 2023: $1,024 · 2024: $577 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $11,219.89 | 2019-2023 | Venovo |
| Abbott Laboratories | $2,699.57 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $878.91 | 2019-2025 | Ingevity+, Latitude Communicator Power Supply, General - Therapies |
| Janssen Pharmaceuticals, INC | $762.22 | 2019-2024 | Xarelto |
| Medtronic, INC. | $733.56 | 2021-2024 | Endurant Iis, Harmony, Linq II |
| Astrazeneca Pharmaceuticals LP | $630.93 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $607.14 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $565.67 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $377.70 | 2019-2025 | |
| Amgen INC. | $342.94 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.72 | 2019-2025 | Jardiance |
| Terumo Medical Corporation | $277.59 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $201.07 | 2022-2025 | Lifevest |
| Philips North America LLC | $100.69 | 2019-2022 | |
| Medtronic Vascular, INC. | $94.25 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $68.02 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $58.47 | 2022-2023 | Verquvo |
| Shockwave Medical, INC | $41.80 | 2025 | |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $41.09 | 2019 | |
| W. L. Gore & Associates, INC. | $38.58 | 2024-2025 | Gore Viabahn Vbx Balloon Expandable Endo |
| Cordis US Corp. | $33.67 | 2022-2024 | Raiden3t |
| Amarin Pharma, INC. | $33.33 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $33.18 | 2025 | Amvuttra |
| Tactile Systems Technology INC | $27.22 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Impulse Dynamics (USA) INC. | $24.19 | 2023 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $21.53 | 2024 | Uptravi, Opsumit |
| Heartflow, INC. | $19.74 | 2022 | |
| Chiesi USA, INC. | $12.70 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Deluca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.